Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study.
Adenocarcinoma of Lung
/ drug therapy
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bevacizumab
/ administration & dosage
Carboplatin
/ administration & dosage
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Case-Control Studies
Female
Follow-Up Studies
Humans
Lung Neoplasms
/ drug therapy
Maintenance Chemotherapy
/ methods
Male
Middle Aged
Pemetrexed
/ administration & dosage
Prognosis
Retrospective Studies
Survival Rate
Antiangiogenic targeted therapy
chemotherapy
pemetrexed
progressive-free survival
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
24
02
2020
revised:
15
04
2020
accepted:
18
04
2020
pubmed:
15
5
2020
medline:
12
3
2021
entrez:
15
5
2020
Statut:
ppublish
Résumé
Pemetrexed and bevacizumab as monotherapies, or in combination, have been approved for maintenance therapy following platinum-based induction in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). The differences in the benefits of bevacizumab for treatment during early or late NSCLC have not yet been characterized. We retrospectively analyzed data from 35 patients with advanced naïve NSCLC who had received pemetrexed/platinum with or without bevacizumab followed by maintenance therapy with pemetrexed alone or pemetrexed plus bevacizumab. The data were analyzed using the Kaplan-Meier method and Cox regression adjusted for risk factors. Patients were grouped according to treatment conditions. Group A received pemetrexed plus platinum followed by pemetrexed alone (Pem-Pt/Pem). Group B received pemetrexed plus platinum followed by pemetrexed and bevacizumab (Group B; Pem-Pt/Pem + Bev). Group C received pemetrexed, platinum, and bevacizumab during induction therapy, and pemetrexed as maintenance therapy (Group C; Pem-Pt + Bev/Pem + Bev). We assessed the significance of introduction of bevacizumab at different stages of treatment. A total of 13 (37.1%) patients were included in Group A, nine patients (25.7%) were included in Group B, and 13 patients (37.1%) were included in Group C. Among the 35 patients, 69.2% were male, and the median age was 59 years (range 40-75). The median progression-free survival (PFS) was 7.7 months (231 days, range 134-410 days) in Group A, 9.3 months (280 days, range 84-565 days) in Group B, and 8.0 months (241 days, range 108-665 days) in Group C. The median PFS was not significantly different among the three groups (P = 0.233). Similarly, bevacizumab did not significantly affect PFS (P = 0.630). The addition of bevacizumab into induction chemotherapy or maintenance therapy provided limited benefits to PFS in our study, but previous studies suggested that bevacizumab may improve disease control. In that way, we presume that early use of bevacizumab may provide a greater benefit.
Sections du résumé
BACKGROUND
Pemetrexed and bevacizumab as monotherapies, or in combination, have been approved for maintenance therapy following platinum-based induction in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). The differences in the benefits of bevacizumab for treatment during early or late NSCLC have not yet been characterized.
METHODS
We retrospectively analyzed data from 35 patients with advanced naïve NSCLC who had received pemetrexed/platinum with or without bevacizumab followed by maintenance therapy with pemetrexed alone or pemetrexed plus bevacizumab. The data were analyzed using the Kaplan-Meier method and Cox regression adjusted for risk factors. Patients were grouped according to treatment conditions. Group A received pemetrexed plus platinum followed by pemetrexed alone (Pem-Pt/Pem). Group B received pemetrexed plus platinum followed by pemetrexed and bevacizumab (Group B; Pem-Pt/Pem + Bev). Group C received pemetrexed, platinum, and bevacizumab during induction therapy, and pemetrexed as maintenance therapy (Group C; Pem-Pt + Bev/Pem + Bev). We assessed the significance of introduction of bevacizumab at different stages of treatment.
RESULTS
A total of 13 (37.1%) patients were included in Group A, nine patients (25.7%) were included in Group B, and 13 patients (37.1%) were included in Group C. Among the 35 patients, 69.2% were male, and the median age was 59 years (range 40-75). The median progression-free survival (PFS) was 7.7 months (231 days, range 134-410 days) in Group A, 9.3 months (280 days, range 84-565 days) in Group B, and 8.0 months (241 days, range 108-665 days) in Group C. The median PFS was not significantly different among the three groups (P = 0.233). Similarly, bevacizumab did not significantly affect PFS (P = 0.630).
CONCLUSIONS
The addition of bevacizumab into induction chemotherapy or maintenance therapy provided limited benefits to PFS in our study, but previous studies suggested that bevacizumab may improve disease control. In that way, we presume that early use of bevacizumab may provide a greater benefit.
Identifiants
pubmed: 32406994
doi: 10.1111/1759-7714.13469
pmc: PMC7327679
doi:
Substances chimiques
Pemetrexed
04Q9AIZ7NO
Bevacizumab
2S9ZZM9Q9V
Carboplatin
BG3F62OND5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1869-1875Informations de copyright
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
J Clin Oncol. 2013 Mar 10;31(8):1009-20
pubmed: 23401441
J Clin Oncol. 2007 Nov 20;25(33):5233-9
pubmed: 18024869
N Engl J Med. 2002 Jan 10;346(2):92-8
pubmed: 11784875
Ann Oncol. 2010 Sep;21(9):1804-1809
pubmed: 20150572
J Clin Oncol. 2009 Mar 10;27(8):1227-34
pubmed: 19188680
Lancet Oncol. 2019 May;20(5):625-635
pubmed: 30975627
Lung Cancer. 2012 Jun;76(3):373-9
pubmed: 22236866
Lancet. 2009 Oct 24;374(9699):1432-40
pubmed: 19767093
Ann Oncol. 2014 Sep;25 Suppl 3:iii27-39
pubmed: 25115305
J Natl Compr Canc Netw. 2019 May 1;17(5.5):574-578
pubmed: 31117034
J Thorac Oncol. 2014 Sep;9(9):1332-9
pubmed: 25122429
J Clin Oncol. 2015 Jul 1;33(19):2197-204
pubmed: 26014294
N Engl J Med. 2006 Dec 14;355(24):2542-50
pubmed: 17167137
J Natl Compr Canc Netw. 2018 Jul;16(7):807-821
pubmed: 30006423
J Clin Oncol. 2009 Mar 20;27(9):1405-12
pubmed: 19224857
Cancer Res. 1997 Mar 15;57(6):1116-23
pubmed: 9067281
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
J Clin Oncol. 2013 Dec 1;31(34):4349-57
pubmed: 24145346
Lancet. 2016 Apr 2;387(10026):1415-1426
pubmed: 26777916
Biomed Res Int. 2018 May 28;2018:5839081
pubmed: 29998136
J Clin Oncol. 2004 Jun 1;22(11):2184-91
pubmed: 15169807
Eur J Cancer. 2016 May;58:30-7
pubmed: 26922170
Clin Ther. 2019 Mar;41(3):518-529
pubmed: 30846285
J Clin Oncol. 2013 Aug 20;31(24):3004-11
pubmed: 23835708
J Clin Oncol. 2004 Oct 1;22(19):3852-9
pubmed: 15326195
Lung Cancer. 2014 Sep;85(3):401-7
pubmed: 25082564
Lancet Oncol. 2010 Aug;11(8):733-40
pubmed: 20650686
Lung Cancer. 2012 Jun;76(3):362-7
pubmed: 22244743
Lancet Oncol. 2012 Mar;13(3):247-55
pubmed: 22341744
J Cancer Res Clin Oncol. 2019 Oct;145(10):2555-2564
pubmed: 31350622
Ann Oncol. 2014 May;25(5):1044-52
pubmed: 24585722